U.S. markets closed

ESSA Pharma Inc. (EPIX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.7500-0.0500 (-2.78%)
At close: 04:00PM EDT
1.6700 -0.08 (-4.57%)
After hours: 04:36PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.8000
Bid1.6700 x 2200
Ask1.8500 x 900
Day's Range1.6600 - 1.8000
52 Week Range1.6600 - 14.8800
Avg. Volume395,507
Market Cap77.128M
Beta (5Y Monthly)1.58
PE Ratio (TTM)N/A
EPS (TTM)-0.8660
Earnings DateNov 16, 2022 - Nov 21, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for EPIX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ESSA Pharma Inc.
    Daily – Vickers Top Buyers & Sellers for 07/21/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • CNW Group

    ESSA Pharma Appoints Philip Kantoff to its Board of Directors

    ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Philip Kantoff, M.D., to its Board of Directors. Dr. Kantoff brings invaluable insight and experience to ESSA as a renowned medical oncologist and leader in the clinical development of new prostate cancer treatments.

  • Investopedia

    Examining Penny Stocks with Technical Analysis for September 2022

    Technical analysis (TA) involves the careful study of a stock's chart patterns and trends. Although this set of skills may seem daunting at first, even beginners can incorporate a few select TA methodologies into their investing strategy to great success.

  • Zacks Small Cap Research

    EPIX: Multiple Ongoing Studies of EPI-7386…

    By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Multiple Ongoing Studies of EPI-7386 ESSA Pharma Inc (NASDAQ:EPIX) is developing EPI-7386 as a treatment for prostate cancer. It is a member of a novel class of compounds known as ‘anitens’, which specifically target the androgen receptor (AR). The AR is the main signaling mechanism driving the growth of prostate